LOG IN
SIGN UP
MARKET
KURA
KURA
Kura Oncology Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
13.51
+0.96
+7.65%
After Hours: 13.51 0 0.00% 16:00 05/27 EDT
OPEN
12.55
PREV CLOSE
12.55
HIGH
13.51
LOW
12.41
VOLUME
419.84K
TURNOVER
0
52 WEEK HIGH
23.71
52 WEEK LOW
10.41
MARKET CAP
900.25M
P/E (TTM)
-6.7889
1D
5D
1M
3M
1Y
5Y
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D.,...
GlobeNewswire · 1d ago
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than its all-time high price ($174.79 vs. $66.50).
Benzinga · 2d ago
Kura Oncology Q1 EPS $(0.49) Beats $(0.52) Estimate
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.52) by 5.77 percent. This is a 6.52 percent decrease over losses of $(0.46) per share from the
Benzinga · 05/04 21:46
BRIEF-Kura Oncology Reports First Quarter 2022 Financial Results
reuters.com · 05/04 21:45
Kura Oncology to Report First Quarter 2022 Financial Results
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first qu...
GlobeNewswire · 04/27 11:30
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Benzinga · 04/13 12:15
The Week Ahead In Biotech (April 10—April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Benzinga · 04/10 20:42
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – – Company to initiate clinical trial of tipifarnib in combina...
GlobeNewswire · 04/08 17:00
No Data
Learn about the latest financial forecast of KURA. Analyze the recent business situations of Kura Oncology Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 9 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average KURA stock price target is 35.88 with a high estimate of 56.00 and a low estimate of 22.00.
Current 13.51
EPS
Actual
Estimate
-0.43-0.32-0.22-0.11
Institutional Holdings
Institutions: 205
Institutional Holdings: 68.61M
% Owned: 102.97%
Shares Outstanding: 66.64M
TypeInstitutionsShares
Increased
52
5.46M
New
27
3.23M
Decreased
40
3.95M
Sold Out
27
7.37M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
Troy Wilson
Chief Operating Officer
Kathleen Ford
Other
Stephen Dale
Other
Kirsten Flowers
Other
Bridget Martell
Secretary
Teresa Bair
Lead Director/Independent Director
Faheem Hasnain
Director
Helen Collins
Director
Carol Schafer
Independent Director
Thomas Malley
Independent Director
Diane Parks
Independent Director
Steven Stein
Independent Director
Mary Szela
No Data
No Data
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. It is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Webull offers kinds of Kura Oncology Inc stock information, including NASDAQ:KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.